Evgen Pharma granted a core patent in Europe and is timely from a commercial perspective

Steve Franklin, CEO of Evgen Pharma, said: “We are delighted by the grant of this core patent in Europe, which further expands our intellectual property position and complements similar grants in the USA, Canada and Australia. This patent grant is timely from a commercial perspective as we are moving close to the announcement of our first Phase II clinical data from SFX-01, which we continue to expect in the first half of this year as part of our ongoing STEM trial in breast cancer.”

Evgen Pharma (LON:EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, this morning announced the grant of a key European patent ascribing intellectual property rights to the Company for a method of stabilising sulforaphane, the naturally occurring compound on which SFX-01, the Company’s lead product, is based.

The grant of this core patent, which expires on 23 January 2028, marks another important step in expanding the Company’s worldwide intellectual property estate surrounding sulforaphane and the Company’s synthetic, stabilised version, SFX-01.

This patent represents the Company’s second process patent grant in Europe and follows the announcement of a manufacturing and scale-up grant in October 2017. Composition-of-matter and manufacturing patents have already been granted in the USA. Patents are also granted, or in the process towards being granted, in other key commercial territories.

The European patent announced today, numbered EP2796140 and entitled Stablilized Sulforaphane, can be viewed at this link: https://register.epo.org/application?number=EP14166888&lng=en&tab=main.

Exclusive worldwide rights to the patent are held by Evgen Pharma under the terms of a licence agreement with PharmAgra Labs Inc., the US laboratory that invented SFX-01.

In line with Company policy, an update on less material patent developments, including grants related to the Company’s sulforaphane analogues, will be included as part of the Company’s full year results.

 

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Evgen Pharma Plc

    More articles like this

    Hardman & Co

    Evgen Pharma plc Interims – Update on clinical progress

    Evgen Pharma plc (LON:EVG) is a virtual pharmaceutical company focused on the development of a synthetic version of sulforaphane, which is known to modulate key signalling pathways involved in cellular protection and inflammation. Evgen’s proprietary technology,

    DirectorsTalk

    INTERVIEW: Evgen Pharma Plc Its all looking positive

    Evgen Pharma Plc (LON:EVG) CEO Dr Stephen Franklin talks to DirectorsTalk about it’s latest interim statement. Stephen reminds us what SFX-01 is and what diseases they are targeting, runs through the main headlines from the interim

    Evgen Pharma Plc

    Evgen Pharma plc “Update re SFX-01 Data at ECTRIMS 2016”

    Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has told DirectorsTalk that the abstract and poster relating to the results of its preclinical study

    Evgen Pharma Plc

    Evgen Pharma plc analysts meeting 31st May

    Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will announce its preliminary results for the year ended 31 March 2016 on Tuesday 31 May